← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.13T	4,451	+545	+14%	$843B
2	2 Amgen AMGN $235B	3,099	+271	+10%	$147B
3	3 Pfizer PFE $169B	2,924	+103	+4%	$92.9B
4	4 McKesson MCK $117B	2,007	+169	+9%	$89.1B
5	5 Becton Dickinson BDX $52B	1,555	+69	+5%	$51.8B
6	6 Novo Nordisk NVO $173B	1,423	+23	+2%	$16B
7	7 AstraZeneca AZN $256B	1,410	+120	+9%	$46.4B
8	8 Regeneron Pharmaceuticals REGN $81.8B	1,391	+144	+12%	$70.7B
9	9 ResMed RMD $33.6B	949	-2	-0.2%	$23.4B
10	10 West Pharmaceutical WST $27B	805	+46	+6%	$19.1B
11	11 Conagra Brands CAG $6.82B	798	+24	+3%	$7.1B
12	12 Teva Pharmaceutical Industries Limited TEVA $48.2B	634	+81	+15%	$21.4B
13	13 Lamb Weston LW $7.38B	627	+2	+0.3%	$5.32B
14	14 The Magnum Ice Cream Company N.V. MICC $11.4B	566	+566	–	$4.38B
15	15 DaVita DVA $12B	535	-28	-5%	$7.55B
16	16 Hims & Hers Health HIMS $6.71B	486	-26	-5%	$5.96B
17	17 Viking Therapeutics VKTX $3.28B	427	+56	+15%	$2.54B
18	18 BellRing Brands BRBR $1.07B	423	-14	-3%	$3.33B
19	19 Madrigal Pharmaceuticals MDGL $10.4B	387	+35	+10%	$13.7B
20	20 Embecta EMBC $361M	363	+9	+3%	$691M
21	21 Inspire Medical Systems INSP $2.02B	343	+18	+6%	$3.12B
22	22 Rhythm Pharmaceuticals RYTM $5.96B	280	+16	+6%	$7.8B
23	23 Scholar Rock SRRK $4.88B	274	+33	+14%	$5.44B
24	24 Biohaven BHVN $1.64B	273	+9	+3%	$1.37B
25	25 MannKind Corp MNKD $984M	258	+24	+10%	$1.03B